ABUS — Arbutus Biopharma Corp
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ABUS
| date | signal | measured base rate |
|---|---|---|
| 2026-08-21 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-07-06 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-02 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-04-24 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-03-03 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-02-02 | Nguyen Tuan Chief Financial Officer | Grant or award | 73.5K | 0.00 | 0 |
| 2026-02-02 | Androski Lindsay President and CEO | Grant or award | 28.0K | 0.00 | 0 |
| 2025-02-14 | McElhaugh Michael J. Interim President & CEO | Grant or award | 177.0K | 0.00 | 0 |
| 2025-02-14 | Sims Karen Chief Medical Officer | Grant or award | 49.3K | 0.00 | 0 |
| 2025-02-14 | Naftzger J. Christopher General Counsel and CCO | Grant or award | 54.3K | 0.00 | 0 |
| 2025-02-14 | HASTINGS DAVID C Chief Financial Officer | Grant or award | 90.1K | 0.00 | 0 |
| 2025-02-04 | McElhaugh Michael J. Interim President & CEO | Open-market sale 10b5-1 plan | 23.8K | 3.28 | 78.0K |
| 2025-02-04 | HASTINGS DAVID C Chief Financial Officer | Open-market sale 10b5-1 plan | 22.2K | 3.28 | 72.8K |
| 2025-02-04 | Sims Karen Chief Medical Officer | Open-market sale 10b5-1 plan | 19.3K | 3.28 | 63.5K |
| 2025-02-04 | Naftzger J. Christopher General Counsel and CCO | Open-market sale 10b5-1 plan | 11.3K | 3.28 | 37.2K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| MORGAN STANLEY | 116.5M | 25.9M |
| Two Seas Capital LP | 83.5M | 18.6M |
| Whitefort Capital Management, LP | 67.2M | 14.9M |
| BlackRock, Inc. | 58.4M | 13.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | 30.1M | 6.7M |
| Rubric Capital Management LP | 29.8M | 6.6M |
| STATE STREET CORP | 28.5M | 6.3M |
| BARCLAYS PLC | 19.4M | 4.3M |
| GEODE CAPITAL MANAGEMENT, LLC | 17.0M | 3.8M |
| ADAR1 Capital Management, LLC | 14.1M | 3.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SC TO-C | 2026-08-21 | — | on EDGAR ↗ |
| 8-K | 2026-08-21 | 2026-08-21 | on EDGAR ↗ |
| 10-Q | 2026-08-12 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 8-K | 2026-07-16 | 2026-07-15 | on EDGAR ↗ |
| 4 | 2026-06-10 | 2026-06-08 | on EDGAR ↗ |
| 4 | 2026-06-10 | 2026-06-08 | on EDGAR ↗ |
| S-8 | 2026-06-05 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Arbutus Biopharma Stock Rises 11% On Launch Of $230 Mln Share Buyback · 2026-08-21
- Why is Arbutus Biopharma stock surging today? · 2026-08-21
- Arbutus Biopharma Launches $230 Mln Share Buyback Via Dutch Auction; Shares Up In Pre-market · 2026-08-21
- Arbutus Biopharma stock surges on $230M buyback plan · 2026-08-21
- Arbutus Biopharma Corp (ABUS) filed form 8-K · 2026-08-21 · SEC EDGAR
- Arbutus Biopharma Corp (ABUS) filed form SC TO-C · 2026-08-21 · SEC EDGAR
Ask the AI about ABUS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →